A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

Rewrite Therapeutics, a US-based DNA writing technologies spinout of University of California, Berkeley, has been acquired by genome editing company Intellia Therapeutics for $45m in an upfront payment and up to an additional $155m in milestone payments through a mix of stock and cash. Rewrite Therapeutics was founded in 2016. It raised $2m in a…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Talking Tech Transfer interview podcast and responsible for the monthly GUV Gazette (sign up here for free).